A detailed history of Jpmorgan Chase & CO transactions in Immatics N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 299,066 shares of IMTX stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
299,066
Previous 321,760 7.05%
Holding current value
$2.05 Million
Previous $3.74 Million 8.72%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$10.93 - $12.92 $248,045 - $293,206
-22,694 Reduced 7.05%
299,066 $3.41 Million
Q2 2024

Aug 12, 2024

BUY
$9.78 - $13.49 $492,031 - $678,681
50,310 Added 18.53%
321,760 $3.74 Million
Q1 2024

May 10, 2024

SELL
$10.23 - $12.94 $205,837 - $260,365
-20,121 Reduced 6.9%
271,450 $2.85 Million
Q4 2023

Feb 12, 2024

SELL
$7.36 - $10.89 $82,866 - $122,610
-11,259 Reduced 3.72%
291,571 $3.07 Million
Q3 2023

Nov 14, 2023

BUY
$11.01 - $12.62 $902,280 - $1.03 Million
81,951 Added 37.1%
302,830 $3.51 Million
Q2 2023

Aug 11, 2023

SELL
$5.92 - $12.72 $28,131 - $60,445
-4,752 Reduced 2.11%
220,879 $2.55 Million
Q1 2023

May 11, 2023

SELL
$6.74 - $9.44 $361,284 - $506,012
-53,603 Reduced 19.2%
225,631 $1.56 Million
Q4 2022

Feb 13, 2023

BUY
$8.05 - $11.58 $222,260 - $319,723
27,610 Added 10.97%
279,234 $2.43 Million
Q3 2022

Nov 14, 2022

BUY
$3.31 - $13.06 $165,840 - $654,345
50,103 Added 24.86%
251,624 $2.52 Million
Q2 2022

Aug 11, 2022

SELL
$6.0 - $9.37 $6,714 - $10,485
-1,119 Reduced 0.55%
201,521 $1.76 Million
Q1 2022

May 11, 2022

BUY
$6.64 - $12.85 $808,446 - $1.56 Million
121,754 Added 150.53%
202,640 $1.62 Million
Q4 2021

Feb 10, 2022

SELL
$10.81 - $14.38 $641,184 - $852,935
-59,314 Reduced 42.31%
80,886 $1.09 Million
Q3 2021

Nov 12, 2021

BUY
$11.58 - $15.46 $1.62 Million - $2.17 Million
140,200 New
140,200 $1.82 Million

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $522M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.